Thermo Fisher Scientific (TMO)
(Delayed Data from NYSE)
$618.46 USD
-5.75 (-0.92%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $618.47 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$618.46 USD
-5.75 (-0.92%)
Updated Sep 11, 2024 04:00 PM ET
After-Market: $618.47 +0.01 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum C VGM
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
IDEXX (IDXX) Earnings Beat Estimates in Q2, Margins Rise
by Zacks Equity Research
IDEXX Laboratories (IDXX) registered strong contribution from its CAG business despite the pandemic-led challenges.
Teleflex (TFX) Beats Q2 Earnings Estimates, Margins Contract
by Zacks Equity Research
Teleflex (TFX) sales grow within the Americas attributable to Vascular Access and respiratory products, driven by COVID-19-led elevated demand.
DaVita (DVA) Earnings Beat Estimates in Q2, Revenues Miss
by Zacks Equity Research
DaVita's (DVA) dialysis services in the United States were solid in Q2.
Exact Sciences' (EXAS) Q2 Earnings Beat, Margin Declines
by Zacks Equity Research
Exact Sciences' (EXAS) legacy screening business sees a decline in revenues in Q2 earnings.
NextGen Healthcare (NXGN) Tops Q1 Earnings & Revenue Estimates
by Zacks Equity Research
NextGen (NXGN) benefited from its Recurring segment in Q1.
Bio-Rad (BIO) Q2 Earnings Beat Estimates, Gross Margin Rises
by Zacks Equity Research
Bio-Rad's (BIO) second-quarter 2020 results reflect strong performance by the Life Sciences segment, boosted by coronavirus-led increased testing demand.
Tandem Diabetes (TNDM) Q2 Earnings & Revenues Top Estimates
by Zacks Equity Research
Tandem Diabetes' (TNDM) strong domestic pump sales and pump shipments boosted the top line.
Integer Holdings (ITGR) Q2 Earnings Miss Estimates, Down Y/Y
by Zacks Equity Research
Integer Holdings' (ITGR) second-quarter results reflect from weak segmental performance and margin contraction.
Stryker (SYK) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Stryker's (SYK) second-quarter earnings reflect weak segmental performance.
OPKO Health (OPK) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
OPKO Health's (OPK) second-quarter results benefit from increase in RAYALDEE prescriptions.
Chemed (CHE) Q2 Earnings Beat Estimates, Margins Decline
by Zacks Equity Research
Chemed (CHE) witnesses solid revenue growth across key subsidiaries in Q2 earnings.
CONMED (CNMD) Q2 Loss Narrower Than Expected, Revenues Top
by Zacks Equity Research
CONMED's (CNMD) core units - General Surgery and Orthopedic Surgery - witnessed revenue decline in Q2.
Merit Medical (MMSI) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Merit Medical (MMSI) reported a drop in revenues at every key operating segment in Q2.
Hologic (HOLX) Q3 Earnings Surpass Estimates, Margins Rise
by Zacks Equity Research
Hologic (HOLX) exhibited robust segmental growth in third-quarter fiscal 2020 driven by strong performance by the Diagnostics segment amid the coronavirus pandemic.
Baxter (BAX) Earnings and Revenues Miss Estimates in Q2
by Zacks Equity Research
Baxter's (BAX) second-quarter earnings reflect weak performance across Medication Delivery, Pharmaceutical and Advanced Surgery business units and contraction in margins.
Cerner (CERN) Q2 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Cerner (CERN) second-quarter results benefit from gains in Subscriptions and Managed services units, and expansion in margins.
The Zacks Analyst Blog Highlights: Turning Point Brands, Medifast, Emergent BioSolutions, Thermo Fisher Scientific and Sempra Energy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Turning Point Brands, Medifast, Emergent BioSolutions, Thermo Fisher Scientific and Sempra Energy
The Zacks Analyst Blog Highlights: Microsoft, Tesla, Thermo Fisher Scientific, ABB and Suncor Energy
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Microsoft, Tesla, Thermo Fisher Scientific, ABB and Suncor Energy
Jobless Claims Rise First Time Since March: 5 Defensive Picks
by Sreoshi Bera
The spike in unemployment claims and looming coronavirus fears have made markets volatile, making defensive picks lucrative investment options.
Top Stock Reports for Microsoft, Tesla & Thermo Fisher
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Microsoft (MSFT), Tesla (TSLA) and Thermo Fisher Scientific (TMO).
Company News for Jul 23, 2020
by Zacks Equity Research
Companies In The News Are: HCA, TMO, ABB, APH.
Should You Buy the Rally in Non-US Stocks?
by John Blank
Or does global growth need to show up first???
Has Thermo Fisher Scientific (TMO) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (TMO) Outperforming Other Medical Stocks This Year?
Thermo Fisher (TMO) Q2 Earnings Beat on COVID-19-Led Sales
by Zacks Equity Research
We are encouraged about Thermo Fisher's (TMO) exceptionally strong year-over-year revenue growth at Life Sciences Solutions segment.
Here's Why You Should Add QIAGEN (QGEN) to Your Portfolio
by Zacks Equity Research
Investors continue to be optimistic about QIAGEN (QGEN) on robust segmental and geographical growth.